Mesalamine is a Small Molecule owned by Dr. Falk Pharma, and is involved in 13 clinical trials, of which 10 were completed, 1 is ongoing, and 2 are planned.

Mesalamine (also known as mesalazine) is an agent derived from sulfasalazine, an antiinflammatory agent. Mesalamine may reduce inflammation through inhibition of cyclooxygenase and prostaglandin production. Mucosal production of arachidonic acid (AA) metabolites, both through the cyclooxygenase pathways, ie, prostanoids, and through the lipoxygenase pathways, ie, leukotrienes (LTs) and hydroxyeicosatetraenoic acids (HETEs), is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin (PG) production in the colon.

The revenue for Mesalamine is expected to reach a total of $2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Mesalamine NPV Report.

Mesalamine is originated and owned by Dr. Falk Pharma. China Medical System Holdings is the other company associated in development or marketing of Mesalamine.

Mesalamine Overview

Mesalazine (Salofalk, Canasa, Salo) is an aminosalicylate anti-inflammatory agent. It is formulated as suppositories, suspension, aerosol foam, enema for rectal route of administration, tablets, film coated tablets and granules for oral route of administration. It is indicated for the treatment of ulcerative colitis, eosinophilic esophagitis and ulcerative proctitis and crohn’s disease. It was under development for the treatment of diverticulitis, collagenous colitis and pediatric ulcerative colitis.

China Medical System Holdings Overview

China Medical System Holdings (CMS), subsidiary of Treasure Sea Ltd, is a pharmaceutical company that markets, promotes and sells pharmaceutical drugs. Its offering product includes plendil, deanxit, xinhuosu, ursofalk, bioflor, combizym, hirudoid, aethoxysklerol, lansoprazole enteric, tacrolimus, cyclosporine, paliperidone, latanoprost, levetiracetam, pons, extendedrelease and doxorubicin hydrochloride liposome, among others. CMS medical aesthetic product comprises vmonalisa, stratamark, mesoestetic-mesohyal, and neauvia hyaluronic series. Its also offer clinical development services. The company’s product pipeline provides various therapeutic fields which include nervous system, ophthalmology, dermatology, endocrine system, oncology, nephrology, immune system, digestive system and anti-infection. CMS is headquartered in Hong Kong city, Hong Kong.

The company reported revenues of (Renminbi) CNY8,337.2 million for the fiscal year ended December 2021 (FY2021), an increase of 20% over FY2020. In FY2021, the company’s operating margin was 40.9%, compared to an operating margin of 38.7% in FY2020. In FY2021, the company recorded a net margin of 36.2%, compared to a net margin of 36.4% in FY2020.

Quick View – Mesalamine

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Mesalamine
Administration Pathway
  • Oral
  • Rectal
Therapeutic Areas
  • Gastrointestinal
Key Companies
  • Sponsor Company: Dr. Falk Pharma
  • Originator: Dr. Falk Pharma
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.